STOCK TITAN

Vertex Pharmaceuticals, Inc. - VRTX STOCK NEWS

Welcome to our dedicated news page for Vertex Pharmaceuticals (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vertex Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vertex Pharmaceuticals's position in the market.

Rhea-AI Summary
Vertex Pharmaceuticals will have management participation in two upcoming investor conferences. Charles Wagner and David Altshuler will participate in a fireside chat at UBS Biopharma Conference on November 9, 2023. Stuart Arbuckle will participate in a fireside chat at Jefferies London Healthcare Conference on November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
-
Rhea-AI Summary
Vertex Pharmaceuticals to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
-
Rhea-AI Summary
Vertex Pharmaceuticals announces appointment of Michel Lagarde to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
management
Rhea-AI Summary
Vertex Pharmaceuticals presents positive longer-term data on VX-880 stem cell therapy for type 1 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
Vertex Pharmaceuticals receives positive opinion for label extension of KAFTRIO in children with cystic fibrosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
Rhea-AI Summary
Three Vertex Pharmaceuticals researchers receive Breakthrough Prize for developing transformative medicines for cystic fibrosis, improving the function of defective CFTR protein. Vertex's approved medicines treat ~90% of CF patients with responsive mutations. Company developing next-in-class CF triple combination therapy in Phase 3 trials and collaborating with Moderna for mRNA therapeutic. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
Rhea-AI Summary
Septerna signs asset purchase agreement with Vertex Pharmaceuticals, receiving $47.5 million upfront payment and potential future payments. Vertex to continue research and development of GPCR program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
Rhea-AI Summary
Vertex Pharmaceuticals to participate in Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary
Vertex Pharmaceuticals appoints E. Morrey Atkinson as Chief Technical Operations Officer and Head of Biopharmaceutical Sciences and Manufacturing Operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
management
Rhea-AI Summary
Vertex Pharmaceuticals Inc. (VRTX) announces the publication of VX-548 preclinical and clinical trial results in the New England Journal of Medicine, showing promise in treating acute pain. The Phase 2 trials demonstrated strong efficacy and a favorable benefit-risk profile, with Phase 3 trials underway. VX-548 has been granted Breakthrough Therapy and Fast Track designations for moderate to severe acute pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
Vertex Pharmaceuticals, Inc.

Nasdaq:VRTX

VRTX Rankings

VRTX Stock Data

102.49B
257.56M
0.11%
97.33%
1.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About VRTX

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.